ArticleFrontiers in medicine2026
Automated radiomics pipeline integrating TotalSpineSeg for Pfirrmann grading of lumbar disc degeneration with SHAP-based interpretability.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pfirrmann grading of lumbar disc degeneration (LDD) is constrained by inter-observer variability. Although radiomics enables objective quantification, the manual segmentation required by existing models is time-consuming and undermines feature reproducibility. TotalSpineSeg, an nnU-Net-based tool, allows fully automated segmentation, yet its integration with radiomics for Pfirrmann grading remains unexplored. This study aimed to develop an automated radiomics pipeline incorporating TotalSpineSeg for Pfirrmann grading of LDD, and to assess whether three-dimensional features contributed discriminative information beyond mid-sagittal two-dimensional radiomics, simple measurements, and frozen ResNet50 embeddings (ImageNet and RadImageNet). Interpretability analysis was applied to identify candidate imaging biomarkers. Methods: Magnetic resonance imaging (MRI) data from 210 patients with LDD yielded 630 disc samples (L3-S1, Pfirrmann Grades I-V). Segmentation was performed automatically with TotalSpineSeg. Of 1,774 extracted radiomics features, 517 were retained through a multi-step selection process. Ten machine learning algorithms were evaluated using a patient-level 80:20 train-test split with 5-fold cross-validation, and SHapley Additive exPlanations (SHAP) analysis was applied for feature interpretation. Results: Automated segmentation averaged 6.9 s per case. The CatBoost model achieved a macro-averaged area under the curve (AUC) of 0.936 (95% confidence interval [CI]: 0.913-0.958) for three-dimensional radiomics, followed by mid-sagittal two-dimensional radiomics (0.916), frozen convolutional neural network (CNN) embeddings (RadImageNet, 0.874; ImageNet, 0.864), and the strongest simple measurement (0.760). For the three-dimensional model, sensitivity and specificity were 63.9% and 93.1%, grade-specific AUCs ranged from 0.876 to 0.978, and SHAP analysis identified the Laplacian of Gaussian first-order minimum, Flatness, and gray-level co-occurrence matrix (GLCM) Imc2 as candidate biomarkers. Conclusions: Integrating TotalSpineSeg with radiomics offers an efficient and interpretable approach to Pfirrmann grading. Three-dimensional features contributed the greatest discriminative information, with a modest increment over two-dimensional radiomics and a significant advantage over simple measurements and frozen ResNet50 embeddings. The candidate biomarkers identified are pathophysiologically meaningful features for LDD assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.